Interim data from the phase 3 DESTINY-Breast05 trial (NCT04622319) shared at the 2025 European Society for Medical Oncology (ESMO) Congress showed improved invasive disease–free survival (IDFS) with fam-trastuzumab deruxtecan-nxki (T-DXd;…
T-DXd Superior to T-DM1 in Improving IDFS/DFS in Residual HER2+ Breast Cancer | Targeted Oncology
